Contrast safety in the cancer patient: Preventing contrast-induced nephropathy

Cancer Imaging

Volumn 8, Issue SPEC. ISS. A, 2008, Pages

  Heiken, Jay P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Contrast media; Kidney (effects of drugs on)

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CARBOPLATIN; CISPLATIN; CONTRAST MEDIUM; DOXORUBICIN; EPIRUBICIN; FUROSEMIDE; GEMCITABINE; IRINOTECAN; MANNITOL; METHOTREXATE; OXALIPLATIN; PACLITAXEL; SODIUM CHLORIDE; TRASTUZUMAB; ZOLEDRONIC ACID;

AGING; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTRAST MEDIUM INDUCED NEPHROPATHY; CONTRAST RADIOGRAPHY; DIABETES MELLITUS; DRUG TREATMENT FAILURE; GLOMERULUS FILTRATION RATE; HUMAN; HYDRATION; HYPERTENSION; HYPERURICEMIA; KIDNEY DYSFUNCTION; MULTIPLE MYELOMA; NEPHROTOXICITY; PATIENT SAFETY; RISK FACTOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KIDNEY DISEASE; NEOPLASM; REVIEW;

CONTRAST MEDIA; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; NEOPLASMS;

EID: 55949105920     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2008.9018     Document Type: Article

References (38)

1. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet 1975; 883: 6.
2. Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. Nephron 1977; 182: 4.
3. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002; 33: 121-6.
4. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. Cancer 2007; 110: 1376-84.
5. Dogan E, Izmirli M, Ceylan K, et al. Incidence of renal insufficiency in cancer patients. Adv Ther 2005; 22: 357-62.
6. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 2003; 181: 1463-71.
7. McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003; 4(suppl 5): S3-9.
8. Katzberg RW, Barrett BJ. Risk of iodinated contrast material-induced nephropathy with intravenous administration. Radiology 2007; 243: 622-6.
9. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004; 183: 1673-89.
10. Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and neprotoxicity. Radiology 1997; 204: 297-312.
11. Anderson RJ, Linas SL, Berns AS, et al. Non-oliguric acute renal failure. N Engl J Med 1977; 296: 1134-8.
12. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75.
13. Rudnick MR, Kesselheim A, Goldfarb S. Contrast-induced nephropathy: how it develops, how to prevent it. Cleve Clin J Med 2006; 73: 75-87.
14. ACR. Contrast nephrotoxicity. ACR Manual on Contrast Media. American College of Radiography; 2008, p. 31-7.
15. Thomsen HS, Morcos SK, members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serum creatinine be measured before contrast medium administration? Eur Radiol 2005; 15: 749-54.
16. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999; 9: 1602-13.
17. Finn WF. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant 2006; 21(suppl 1); i2-10.
18. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. N Engl J Med 1989; 320: 143-9.
19. Lin J, Bonventre JV. Prevention of radiocontrast nephropathy. Curr Opin Nephrol Hypertens 2005; 14: 105-10.
20. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(suppl 1): S1-266 (also available at http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm; accessed 3 September 2004).
21. Herts BR, Schneider E, Poggio ED, Obuchowski NA, Baker ME. Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels. Radiology 2008; 248: 106-13.
22. Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation in 1,000 cases. J Am Coll Cardiol 1998; 32: 1861-5.
23. Ramirez G, O'Neill WM, Lambert R, et al. Cholesterol embolization: a complication of angiography. Arch Intern Med 1978; 138: 1430-2.
24. Thomsen HS, Morcos SK, Erley CM, et al. The ACTIVE trial: comparison of the effects on renal function of Iomeprol-400 and Iodizanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 2008; 43: 170-8.
25. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography. A double-blind comparison of Iodixanol and Iopamidol. Invest Radiol 2006; 41: 815-21.
26. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol 2008; 191: 151-7.
27. Moore RD, Steinberg EP, Powe NR, et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 1992; 182: 649-55.
28. Barrett BJ, Carlisle EJ. Meta-analysis of the relatively nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171-8.
29. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney International 2005; 68: 2256-63.
30. Carraro M, Malalan F, Antonione R, et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 1998; 8: 144-7.
31. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 2006; 239: 392-7.
32. Heller CA, Knapp J, Halliday J, et al. Failure to demonstrate contrast nephrotoxicity. Med J Aust 1991; 155: 329-32.
33. Newhouse RH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 2008; 191: 376-82.
34. Thomsen HS. Current evidence on prevention and management of contrast-induced nephropathy. Eur Radiol 2007; 17(suppl 6): F33-8.
35. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-34.
36. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1993; 331: 1416-20.
37. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413-15.
38. Dussol B, Morange S, Loudoun A, et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006; 21: 2120-6.